5.5 people die from cancer every minute in China alone and every year there are more than 4.5 million new cases diagnosed.
Infigratinib (BGJ398) is an investigational, orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer) and urothelial carcinoma (bladder cancer).
BBP-398 is an allosteric SHP2 inhibitor designed to inhibit wild-type SHP2, offering the potential to treat the variety of tumors that rely on SHP2 activity for proliferation and survival. SHP2 binds to RTKs and immune checkpoint receptors to regulate their signaling.
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.